ArticleWorld journal of gastroenterology2025
Clinical features of early esophageal neoplastic lesions at different stages and efficacy and prognosis after endoscopic submucosal dissection.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Can bile salts affect the contractile oesophageal activity associated with gastroesophageal reflux disease?World journal of gastroenterology · 2026Article
- Endoscopic submucosal dissection in early esophageal neoplasia: Celebrating efficacy, confronting heterogeneity, and refining surveillance for high-risk patients.World journal of clinical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer is a common malignancy, and endoscopic submucosal dissection (ESD) is the treatment of choice for early esophageal cancer.
aimTo analyze clinicopathological features, ESD efficacy, and prognostic factors of differentiated esophageal neoplasms to optimize management strategies.
methodsA total of 264 Lesions in 245 patients treated with ESD (2014-2022) were retrospectively analyzed. Lesions were categorized as low-grade intraepithelial neoplasia (LGIN), high-grade intraepithelial neoplasia, early-stage carcinoma, or superficial carcinoma. Clinicopathological data and outcomes were compared.
resultsEarly-stage cancers showed more surface vesicles than LGIN (
conclusionDifferentiated esophageal neoplasms exhibit distinct clinicopathological features. ESD provides durable efficacy, but high-risk patients (older age, prior cancer) require vigilant surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.